Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: A EuroSIDA study

Journal of Infectious Diseases

Volumn 194, Issue 5, 2006, Pages 633-641

  Podlekareva, Daria ^a   Mocroft, Amanda ^b   Dragsted, Ulrik B ^a   Ledergerber, Bruno ^d   Beniowski, Marek ^e   Lazzarin, Adriano ^f   Weber, Jonathan ^c   Clumeck, Nathan ^g   Vetter, Norbert ^h   Phillips, Andrew ^b   Lundgren, Jens D ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^h Pulmologisches Zentrum   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CYTOMEGALOVIRUS; DIAGNOSTIC VALUE; ESOPHAGUS CANDIDIASIS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; POISSON DISTRIBUTION; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; TOXOPLASMA GONDII;

EID: 33748039441     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/506366     Document Type: Article

References (21)

1. Mocroft A, Youle M, Phillips AN, et al. The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. Arch Intern Med 1998; 158:491-7.
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-9.
3. Hanson DL, Chu SY, Farizo KM, Ward JW. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group. Arch Intern Med 1995; 155:1537-42.
4. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons-2002 recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2002; 51:1-46.
5. Law MG, de Winter L, McDonald A, Cooper DA, Kaldor JM. AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment. AIDS 1999; 13:263-9.
6. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349:1443-5.
7. Bartlett JG, Gallant J, eds. 2004 medical management of HIV infection. Baltimore, MD: John Hopkins Medicine Health Publishing Business Group, 2004:333-5.
8. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322:161-5.
9. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
10. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124:633-42.
11. Thiebaut R, Chene G, Jacqmin-Gadda H, et al. Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001. J Acquir Immune Defic Syndr 2003; 33:380-6.
12. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002; 185:178-87.
13. Kirk O, Gatell JM, Mocroft A, et al. infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med 2000; 162:865-72.
14. The Antiretroviral Therapy Cohort Collaboration. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41:1772-82.
15. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-9.
16. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
17. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-46.
18. Lipman M, Breen R. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 2006; 19:20-5.
19. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-6.
20. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999; 130:570-7.
21. Hennessey KA, Giorgi JV, Kaplan AH, et al. AIDS onset at high CD4+ cell levels is associated with high HIV load. AIDS Res Hum Retroviruses 2000; 16:103-7.